பிரையன் கள்ளி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from பிரையன் கள்ளி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In பிரையன் கள்ளி Today - Breaking & Trending Today
Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Lineage Cell Therapeutics (NYSEMKT:LCTX) were soaring by 19.4% as of 12:01 p.m. EDT on Tuesday. The big gain came after the company announced positive news from a phase 1/2a study evaluating OpRegen in treating dry age-related macular degeneration (AMD). So what Lineage Cell Therapeutics reported it observed restoration of retinal tissue in two additional patients in its study of OpRegen. The company reported its first case of retinal restoration last year. CEO Brian Culley said, To our knowledge, these three patients represent the only examples of an experimental treatment for dry AMD demonstrating a reduct ....
Operator Welcome to the Lineage Cell Therapeutics first-quarter 2021 conference call. [Operator instructions] An audio webcast of this call is available on the Investors section of Lineage s website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage and recordings, reproduction, or transmission of this call without the expressed written consent of Lineage are strictly prohibited. As a reminder, today s call is being recorded. I would now like to introduce your host for today s conference, Ioana Hone, director of investor relations at Lineage. Ms. Hone, please go ahead. Ioana Hone Director of Investor Relations ....
Lineage to Receive $2 Million Upfront and up to $67 Million in Development and Commercial Milestones Plus Royalties Partnership Leverages the VAC Allogeneic Cancer Immunotherapy Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate Immunomic Will be Responsible for Future Clinical Development and Commercialization Costs
CARLSBAD, Calif. (BUSINESS WIRE) Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced a worldwide license and development collaboration agreement with Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. The collaboration will generate a novel product candidate derived from Lineage’s VAC allogeneic cance ....
Operator Ladies and gentlemen, welcome to the Lineage Cell Therapeutics fourth-quarter and year-end 2020 conference call. [Operator instructions] An audio webcast of this call is available on the Investors section of Lineage s website at www.lineagecell.com. This call is subject to copyright and is property of Lineage. And recordings, reproduction or transmission of this call without expressed written consent of Lineage are strictly prohibited. As a reminder, today s call is being recorded. I would now like to introduce your host for today s conference, Ioana Hone, director of investor relations at Lineage. Ms. Hone, please go ahead. Ioana Hone Director of Investor Relations ....